nodes	percent_of_prediction	percent_of_DWPC	metapath
Erlotinib—LTK—tongue—cleft lip	0.0327	0.149	CbGeAlD
Erlotinib—LTK—mouth—cleft lip	0.022	0.1	CbGeAlD
Erlotinib—ULK3—tongue—cleft lip	0.0178	0.0811	CbGeAlD
Erlotinib—ULK3—mouth—cleft lip	0.012	0.0546	CbGeAlD
Erlotinib—NR1I2—head—cleft lip	0.00795	0.0362	CbGeAlD
Erlotinib—LTK—head—cleft lip	0.00795	0.0362	CbGeAlD
Erlotinib—EGFR—telencephalon—cleft lip	0.0075	0.0342	CbGeAlD
Erlotinib—PIP4K2C—telencephalon—cleft lip	0.00727	0.0331	CbGeAlD
Erlotinib—ULK3—telencephalon—cleft lip	0.00694	0.0316	CbGeAlD
Erlotinib—AURKC—head—cleft lip	0.00686	0.0313	CbGeAlD
Erlotinib—MKNK1—telencephalon—cleft lip	0.00653	0.0298	CbGeAlD
Erlotinib—EPHA6—head—cleft lip	0.00635	0.029	CbGeAlD
Erlotinib—JAK3—head—cleft lip	0.00635	0.029	CbGeAlD
Erlotinib—SLK—telencephalon—cleft lip	0.00619	0.0282	CbGeAlD
Erlotinib—MAP3K19—head—cleft lip	0.00577	0.0263	CbGeAlD
Erlotinib—MAP2K5—telencephalon—cleft lip	0.0048	0.0219	CbGeAlD
Erlotinib—ABL1—embryo—cleft lip	0.00456	0.0208	CbGeAlD
Erlotinib—PIP4K2C—head—cleft lip	0.00453	0.0206	CbGeAlD
Erlotinib—ULK3—head—cleft lip	0.00432	0.0197	CbGeAlD
Erlotinib—MKNK1—head—cleft lip	0.00407	0.0185	CbGeAlD
Erlotinib—CYP1A1—mouth—cleft lip	0.00383	0.0174	CbGeAlD
Erlotinib—SLCO2B1—telencephalon—cleft lip	0.00374	0.017	CbGeAlD
Erlotinib—ABL1—telencephalon—cleft lip	0.00371	0.0169	CbGeAlD
Erlotinib—STK10—head—cleft lip	0.00335	0.0153	CbGeAlD
Erlotinib—CYP1B1—telencephalon—cleft lip	0.00314	0.0143	CbGeAlD
Erlotinib—MAP2K5—head—cleft lip	0.00299	0.0136	CbGeAlD
Erlotinib—ABCG2—telencephalon—cleft lip	0.00234	0.0107	CbGeAlD
Erlotinib—SLCO2B1—head—cleft lip	0.00233	0.0106	CbGeAlD
Erlotinib—ABL1—head—cleft lip	0.00231	0.0105	CbGeAlD
Erlotinib—CYP1B1—head—cleft lip	0.00195	0.00891	CbGeAlD
Erlotinib—CYP2D6—telencephalon—cleft lip	0.0016	0.0073	CbGeAlD
Erlotinib—ABCB1—embryo—cleft lip	0.00142	0.00646	CbGeAlD
Erlotinib—CYP1A1—head—cleft lip	0.00138	0.0063	CbGeAlD
Erlotinib—ABCB1—telencephalon—cleft lip	0.00115	0.00525	CbGeAlD
Erlotinib—CYP2D6—head—cleft lip	0.000998	0.00455	CbGeAlD
Erlotinib—ABCB1—head—cleft lip	0.000718	0.00327	CbGeAlD
Erlotinib—EGFR—NGF signalling via TRKA from the plasma membrane—FGFR3—cleft lip	0.000354	0.000454	CbGpPWpGaD
Erlotinib—EGFR—Signaling by ERBB4—FGF2—cleft lip	0.000349	0.000447	CbGpPWpGaD
Erlotinib—ABL1—DNA Damage Response (only ATM dependent)—MYC—cleft lip	0.000348	0.000446	CbGpPWpGaD
Erlotinib—JAK3—Immune System—FGF9—cleft lip	0.000347	0.000444	CbGpPWpGaD
Erlotinib—EGFR—Signaling by GPCR—WNT3—cleft lip	0.000343	0.000439	CbGpPWpGaD
Erlotinib—EGFR—Adaptive Immune System—FGF7—cleft lip	0.000342	0.000438	CbGpPWpGaD
Erlotinib—ABL1—Integrated Pancreatic Cancer Pathway—FGF2—cleft lip	0.00034	0.000436	CbGpPWpGaD
Erlotinib—MKNK1—Signaling Pathways—PTCH1—cleft lip	0.000336	0.000431	CbGpPWpGaD
Erlotinib—CYP1A2—Biological oxidations—MTR—cleft lip	0.000336	0.000431	CbGpPWpGaD
Erlotinib—ALB—Transmembrane transport of small molecules—ABCA4—cleft lip	0.000334	0.000428	CbGpPWpGaD
Erlotinib—EGFR—Downstream signal transduction—FGF2—cleft lip	0.000333	0.000427	CbGpPWpGaD
Erlotinib—EGFR—Signaling by FGFR—FGF2—cleft lip	0.000332	0.000425	CbGpPWpGaD
Erlotinib—EGFR—Immune System—IRF6—cleft lip	0.00033	0.000423	CbGpPWpGaD
Erlotinib—EGFR—Signaling by ERBB2—FGF2—cleft lip	0.00033	0.000423	CbGpPWpGaD
Erlotinib—EGFR—DAP12 signaling—FGF2—cleft lip	0.000328	0.000421	CbGpPWpGaD
Erlotinib—EGFR—Innate Immune System—FGF8—cleft lip	0.000328	0.00042	CbGpPWpGaD
Erlotinib—EGFR—EGF/EGFR Signaling Pathway—NOS3—cleft lip	0.000327	0.000419	CbGpPWpGaD
Erlotinib—EGFR—Disease—ABCA4—cleft lip	0.000325	0.000416	CbGpPWpGaD
Erlotinib—EGFR—Downstream signaling events of B Cell Receptor (BCR)—FGF2—cleft lip	0.000324	0.000415	CbGpPWpGaD
Erlotinib—EGFR—Adaptive Immune System—FGF8—cleft lip	0.000315	0.000404	CbGpPWpGaD
Erlotinib—ABL1—Innate Immune System—FGF3—cleft lip	0.000313	0.000401	CbGpPWpGaD
Erlotinib—ABL1—PDGFR-beta signaling pathway—MYC—cleft lip	0.000312	0.0004	CbGpPWpGaD
Erlotinib—EGFR—Signaling by NGF—FGFR2—cleft lip	0.000309	0.000396	CbGpPWpGaD
Erlotinib—EGFR—Fc epsilon receptor (FCERI) signaling—FGF2—cleft lip	0.000309	0.000396	CbGpPWpGaD
Erlotinib—EGFR—Signaling by FGFR in disease—FGF2—cleft lip	0.000309	0.000396	CbGpPWpGaD
Erlotinib—EGFR—DAP12 interactions—FGF2—cleft lip	0.000309	0.000396	CbGpPWpGaD
Erlotinib—EGFR—Signaling by EGFR—FGF2—cleft lip	0.000306	0.000392	CbGpPWpGaD
Erlotinib—JAK3—Signaling Pathways—FGF7—cleft lip	0.000306	0.000392	CbGpPWpGaD
Erlotinib—JAK3—Signaling Pathways—SPRY2—cleft lip	0.000306	0.000392	CbGpPWpGaD
Erlotinib—ABL1—Axon guidance—FGFR1—cleft lip	0.000305	0.000391	CbGpPWpGaD
Erlotinib—MKNK1—Signaling Pathways—FGF3—cleft lip	0.000305	0.000391	CbGpPWpGaD
Erlotinib—ABL1—Innate Immune System—FGF9—cleft lip	0.000305	0.000391	CbGpPWpGaD
Erlotinib—EGFR—Signaling by EGFR in Cancer—FGF2—cleft lip	0.000303	0.000389	CbGpPWpGaD
Erlotinib—EGFR—Signaling by PDGF—FGF2—cleft lip	0.000302	0.000387	CbGpPWpGaD
Erlotinib—JAK3—Hemostasis—NOS3—cleft lip	0.000301	0.000385	CbGpPWpGaD
Erlotinib—MKNK1—Signaling Pathways—FGF9—cleft lip	0.000297	0.000381	CbGpPWpGaD
Erlotinib—EGFR—Disease—SLC19A1—cleft lip	0.000297	0.00038	CbGpPWpGaD
Erlotinib—ABCB1—Transmembrane transport of small molecules—ABCA4—cleft lip	0.000293	0.000375	CbGpPWpGaD
Erlotinib—JAK3—Immune System—FGF10—cleft lip	0.000293	0.000375	CbGpPWpGaD
Erlotinib—ABL1—Developmental Biology—FGF10—cleft lip	0.000291	0.000373	CbGpPWpGaD
Erlotinib—EGFR—Integrated Pancreatic Cancer Pathway—FGF2—cleft lip	0.000291	0.000372	CbGpPWpGaD
Erlotinib—EGFR—Disease—WNT3—cleft lip	0.000289	0.000371	CbGpPWpGaD
Erlotinib—EGFR—Signaling by NGF—FGFR1—cleft lip	0.000288	0.000369	CbGpPWpGaD
Erlotinib—MKNK1—Disease—FGFR2—cleft lip	0.000287	0.000368	CbGpPWpGaD
Erlotinib—EGFR—B Cell Activation—FGF2—cleft lip	0.000286	0.000366	CbGpPWpGaD
Erlotinib—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—MYC—cleft lip	0.000285	0.000365	CbGpPWpGaD
Erlotinib—JAK3—Signaling Pathways—FGF8—cleft lip	0.000283	0.000362	CbGpPWpGaD
Erlotinib—EGFR—Spinal Cord Injury—MYC—cleft lip	0.000279	0.000358	CbGpPWpGaD
Erlotinib—MKNK1—Disease—MTHFR—cleft lip	0.000277	0.000354	CbGpPWpGaD
Erlotinib—EGFR—NGF signalling via TRKA from the plasma membrane—FGF2—cleft lip	0.000274	0.000351	CbGpPWpGaD
Erlotinib—UGT1A1—Metabolism—SLC19A1—cleft lip	0.000274	0.00035	CbGpPWpGaD
Erlotinib—EGFR—Signaling by NGF—FGFR3—cleft lip	0.000272	0.000349	CbGpPWpGaD
Erlotinib—ABL1—Integrated Breast Cancer Pathway—MYC—cleft lip	0.000268	0.000344	CbGpPWpGaD
Erlotinib—MKNK1—Disease—FGFR1—cleft lip	0.000268	0.000343	CbGpPWpGaD
Erlotinib—EGFR—Innate Immune System—FGF3—cleft lip	0.000267	0.000342	CbGpPWpGaD
Erlotinib—ABL1—Immune System—SUMO1—cleft lip	0.000265	0.00034	CbGpPWpGaD
Erlotinib—EGFR—Axon guidance—FGFR1—cleft lip	0.000261	0.000334	CbGpPWpGaD
Erlotinib—EGFR—Innate Immune System—FGF9—cleft lip	0.000261	0.000334	CbGpPWpGaD
Erlotinib—CYP3A4—Biological oxidations—MTR—cleft lip	0.00026	0.000333	CbGpPWpGaD
Erlotinib—ABL1—Innate Immune System—FGF10—cleft lip	0.000257	0.000329	CbGpPWpGaD
Erlotinib—EGFR—Adaptive Immune System—FGF3—cleft lip	0.000257	0.000329	CbGpPWpGaD
Erlotinib—CYP1B1—Metabolism—SLC19A1—cleft lip	0.000255	0.000327	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—WNT9B—cleft lip	0.000255	0.000327	CbGpPWpGaD
Erlotinib—NR1I2—Generic Transcription Pathway—MYC—cleft lip	0.000254	0.000325	CbGpPWpGaD
Erlotinib—JAK3—Signaling Pathways—PTCH1—cleft lip	0.000254	0.000325	CbGpPWpGaD
Erlotinib—MKNK1—Disease—FGFR3—cleft lip	0.000253	0.000324	CbGpPWpGaD
Erlotinib—MKNK1—Signaling Pathways—FGF10—cleft lip	0.000251	0.000321	CbGpPWpGaD
Erlotinib—EGFR—Adaptive Immune System—FGF9—cleft lip	0.00025	0.00032	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—FGF7—cleft lip	0.00025	0.00032	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—SPRY2—cleft lip	0.00025	0.00032	CbGpPWpGaD
Erlotinib—EGFR—Developmental Biology—FGF10—cleft lip	0.000249	0.000319	CbGpPWpGaD
Erlotinib—EGFR—Disease—TCN2—cleft lip	0.000246	0.000315	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—NOG—cleft lip	0.000244	0.000313	CbGpPWpGaD
Erlotinib—ABL1—Immune System—FGF7—cleft lip	0.000242	0.000311	CbGpPWpGaD
Erlotinib—CYP1A2—Aryl Hydrocarbon Receptor—MYC—cleft lip	0.000239	0.000306	CbGpPWpGaD
Erlotinib—ABCB1—Integrated Pancreatic Cancer Pathway—TYMS—cleft lip	0.000238	0.000304	CbGpPWpGaD
Erlotinib—JAK3—Immune System—FGFR2—cleft lip	0.000235	0.000301	CbGpPWpGaD
Erlotinib—ABCG2—Metabolism—SLC19A1—cleft lip	0.000232	0.000297	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—FGF8—cleft lip	0.00023	0.000295	CbGpPWpGaD
Erlotinib—JAK3—Signaling Pathways—FGF3—cleft lip	0.00023	0.000295	CbGpPWpGaD
Erlotinib—EGFR—Integrated Breast Cancer Pathway—MYC—cleft lip	0.000229	0.000294	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—ABCA4—cleft lip	0.000227	0.000291	CbGpPWpGaD
Erlotinib—UGT1A1—Metabolism—TCN2—cleft lip	0.000227	0.00029	CbGpPWpGaD
Erlotinib—EGFR—Immune System—SUMO1—cleft lip	0.000227	0.00029	CbGpPWpGaD
Erlotinib—JAK3—Signaling Pathways—FGF9—cleft lip	0.000224	0.000287	CbGpPWpGaD
Erlotinib—ABL1—Immune System—FGF8—cleft lip	0.000224	0.000287	CbGpPWpGaD
Erlotinib—ABL1—Integrated Pancreatic Cancer Pathway—MYC—cleft lip	0.000222	0.000285	CbGpPWpGaD
Erlotinib—EGFR—Innate Immune System—FGF10—cleft lip	0.00022	0.000281	CbGpPWpGaD
Erlotinib—JAK3—Immune System—FGFR1—cleft lip	0.000219	0.00028	CbGpPWpGaD
Erlotinib—ABL1—Developmental Biology—FGFR1—cleft lip	0.000218	0.000279	CbGpPWpGaD
Erlotinib—CYP1B1—Metabolism—TCN2—cleft lip	0.000211	0.000271	CbGpPWpGaD
Erlotinib—EGFR—Adaptive Immune System—FGF10—cleft lip	0.000211	0.00027	CbGpPWpGaD
Erlotinib—EGFR—MAPK Signaling Pathway—MYC—cleft lip	0.000211	0.00027	CbGpPWpGaD
Erlotinib—EGFR—Signaling by NGF—FGF2—cleft lip	0.00021	0.00027	CbGpPWpGaD
Erlotinib—EGFR—Immune System—FGF7—cleft lip	0.000207	0.000265	CbGpPWpGaD
Erlotinib—JAK3—Immune System—FGFR3—cleft lip	0.000207	0.000265	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—PTCH1—cleft lip	0.000207	0.000265	CbGpPWpGaD
Erlotinib—ABL1—Innate Immune System—FGFR2—cleft lip	0.000206	0.000264	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—WNT3—cleft lip	0.000203	0.000259	CbGpPWpGaD
Erlotinib—MKNK1—Signaling Pathways—FGFR2—cleft lip	0.000201	0.000258	CbGpPWpGaD
Erlotinib—ABCB1—Integrated Pancreatic Cancer Pathway—FGFR1—cleft lip	0.000201	0.000257	CbGpPWpGaD
Erlotinib—MKNK1—Disease—FGF2—cleft lip	0.000196	0.000251	CbGpPWpGaD
Erlotinib—MKNK1—Disease—NOS3—cleft lip	0.000193	0.000247	CbGpPWpGaD
Erlotinib—ABL1—Innate Immune System—FGFR1—cleft lip	0.000192	0.000246	CbGpPWpGaD
Erlotinib—ABCG2—Metabolism—TCN2—cleft lip	0.000192	0.000246	CbGpPWpGaD
Erlotinib—EGFR—Disease—FGF7—cleft lip	0.000191	0.000245	CbGpPWpGaD
Erlotinib—EGFR—Disease—SPRY2—cleft lip	0.000191	0.000245	CbGpPWpGaD
Erlotinib—EGFR—Immune System—FGF8—cleft lip	0.000191	0.000245	CbGpPWpGaD
Erlotinib—EGFR—Integrated Pancreatic Cancer Pathway—MYC—cleft lip	0.00019	0.000243	CbGpPWpGaD
Erlotinib—JAK3—Signaling Pathways—FGF10—cleft lip	0.000189	0.000242	CbGpPWpGaD
Erlotinib—EGFR—Signaling by GPCR—PTCH1—cleft lip	0.000188	0.000241	CbGpPWpGaD
Erlotinib—MKNK1—Signaling Pathways—FGFR1—cleft lip	0.000188	0.00024	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—FGF3—cleft lip	0.000188	0.00024	CbGpPWpGaD
Erlotinib—EGFR—Developmental Biology—FGFR1—cleft lip	0.000186	0.000238	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—FGF9—cleft lip	0.000183	0.000234	CbGpPWpGaD
Erlotinib—ABL1—Immune System—FGF3—cleft lip	0.000182	0.000233	CbGpPWpGaD
Erlotinib—ABL1—Innate Immune System—FGFR3—cleft lip	0.000182	0.000233	CbGpPWpGaD
Erlotinib—ABL1—Immune System—FGF9—cleft lip	0.000178	0.000227	CbGpPWpGaD
Erlotinib—MKNK1—Signaling Pathways—FGFR3—cleft lip	0.000177	0.000227	CbGpPWpGaD
Erlotinib—EGFR—Disease—FGF8—cleft lip	0.000177	0.000226	CbGpPWpGaD
Erlotinib—EGFR—Innate Immune System—FGFR2—cleft lip	0.000176	0.000226	CbGpPWpGaD
Erlotinib—EGFR—Disease—MTR—cleft lip	0.00017	0.000218	CbGpPWpGaD
Erlotinib—EGFR—Adaptive Immune System—FGFR2—cleft lip	0.000169	0.000217	CbGpPWpGaD
Erlotinib—CYP3A5—Metabolism—SLC19A1—cleft lip	0.000166	0.000213	CbGpPWpGaD
Erlotinib—EGFR—Innate Immune System—FGFR1—cleft lip	0.000164	0.000211	CbGpPWpGaD
Erlotinib—JAK3—Immune System—FGF2—cleft lip	0.00016	0.000205	CbGpPWpGaD
Erlotinib—ABL1—Developmental Biology—FGF2—cleft lip	0.000159	0.000204	CbGpPWpGaD
Erlotinib—EGFR—Adaptive Immune System—FGFR1—cleft lip	0.000158	0.000202	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism—SLC19A1—cleft lip	0.000157	0.000201	CbGpPWpGaD
Erlotinib—UGT1A1—Metabolism—MTR—cleft lip	0.000157	0.000201	CbGpPWpGaD
Erlotinib—EGFR—Immune System—FGF3—cleft lip	0.000156	0.000199	CbGpPWpGaD
Erlotinib—EGFR—Innate Immune System—FGFR3—cleft lip	0.000155	0.000199	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—FGF10—cleft lip	0.000154	0.000198	CbGpPWpGaD
Erlotinib—ABL1—Hemostasis—NOS3—cleft lip	0.000154	0.000197	CbGpPWpGaD
Erlotinib—JAK3—Signaling Pathways—FGFR2—cleft lip	0.000152	0.000194	CbGpPWpGaD
Erlotinib—EGFR—Immune System—FGF9—cleft lip	0.000152	0.000194	CbGpPWpGaD
Erlotinib—ABL1—Immune System—FGF10—cleft lip	0.00015	0.000192	CbGpPWpGaD
Erlotinib—EGFR—Adaptive Immune System—FGFR3—cleft lip	0.000149	0.000191	CbGpPWpGaD
Erlotinib—ABCB1—Integrated Pancreatic Cancer Pathway—FGF2—cleft lip	0.000147	0.000188	CbGpPWpGaD
Erlotinib—CYP1B1—Metabolism—MTR—cleft lip	0.000147	0.000188	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism—SLC19A1—cleft lip	0.000144	0.000184	CbGpPWpGaD
Erlotinib—EGFR—Disease—FGF3—cleft lip	0.000144	0.000184	CbGpPWpGaD
Erlotinib—ALB—Metabolism—SLC19A1—cleft lip	0.000143	0.000183	CbGpPWpGaD
Erlotinib—JAK3—Signaling Pathways—FGFR1—cleft lip	0.000141	0.000181	CbGpPWpGaD
Erlotinib—ABL1—Innate Immune System—FGF2—cleft lip	0.00014	0.00018	CbGpPWpGaD
Erlotinib—EGFR—Disease—FGF9—cleft lip	0.00014	0.000179	CbGpPWpGaD
Erlotinib—CYP3A5—Metabolism—TCN2—cleft lip	0.000138	0.000176	CbGpPWpGaD
Erlotinib—MKNK1—Signaling Pathways—FGF2—cleft lip	0.000137	0.000176	CbGpPWpGaD
Erlotinib—EGFR—Developmental Biology—FGF2—cleft lip	0.000136	0.000174	CbGpPWpGaD
Erlotinib—MKNK1—Signaling Pathways—NOS3—cleft lip	0.000135	0.000173	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—SPRY2—cleft lip	0.000134	0.000172	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—FGF7—cleft lip	0.000134	0.000172	CbGpPWpGaD
Erlotinib—JAK3—Signaling Pathways—FGFR3—cleft lip	0.000134	0.000171	CbGpPWpGaD
Erlotinib—ABCG2—Metabolism—MTR—cleft lip	0.000133	0.000171	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism—TCN2—cleft lip	0.00013	0.000167	CbGpPWpGaD
Erlotinib—EGFR—Immune System—FGF10—cleft lip	0.000128	0.000164	CbGpPWpGaD
Erlotinib—MKNK1—Disease—MYC—cleft lip	0.000128	0.000164	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—SLC19A1—cleft lip	0.000125	0.000161	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—FGFR2—cleft lip	0.000124	0.000159	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—FGF8—cleft lip	0.000124	0.000158	CbGpPWpGaD
Erlotinib—NR1I2—Gene Expression—MYC—cleft lip	0.000122	0.000157	CbGpPWpGaD
Erlotinib—ABL1—Immune System—FGFR2—cleft lip	0.00012	0.000154	CbGpPWpGaD
Erlotinib—EGFR—Innate Immune System—FGF2—cleft lip	0.00012	0.000154	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism—TCN2—cleft lip	0.000119	0.000153	CbGpPWpGaD
Erlotinib—ALB—Metabolism—TCN2—cleft lip	0.000119	0.000152	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—SLC19A1—cleft lip	0.000118	0.000151	CbGpPWpGaD
Erlotinib—EGFR—Disease—FGF10—cleft lip	0.000118	0.000151	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—FGFR1—cleft lip	0.000115	0.000148	CbGpPWpGaD
Erlotinib—EGFR—Adaptive Immune System—FGF2—cleft lip	0.000115	0.000148	CbGpPWpGaD
Erlotinib—ABL1—Immune System—FGFR1—cleft lip	0.000112	0.000144	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—PTCH1—cleft lip	0.000111	0.000142	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—FGFR3—cleft lip	0.000109	0.00014	CbGpPWpGaD
Erlotinib—ABL1—Immune System—FGFR3—cleft lip	0.000106	0.000136	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—TCN2—cleft lip	0.000104	0.000133	CbGpPWpGaD
Erlotinib—JAK3—Signaling Pathways—FGF2—cleft lip	0.000103	0.000132	CbGpPWpGaD
Erlotinib—EGFR—Immune System—FGFR2—cleft lip	0.000103	0.000132	CbGpPWpGaD
Erlotinib—JAK3—Signaling Pathways—NOS3—cleft lip	0.000102	0.000131	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—FGF3—cleft lip	0.000101	0.000129	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—SLC19A1—cleft lip	0.0001	0.000128	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—FGF9—cleft lip	9.81e-05	0.000126	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—TCN2—cleft lip	9.8e-05	0.000125	CbGpPWpGaD
Erlotinib—UGT1A1—Metabolism—TYMS—cleft lip	9.63e-05	0.000123	CbGpPWpGaD
Erlotinib—ABCB1—Integrated Pancreatic Cancer Pathway—MYC—cleft lip	9.59e-05	0.000123	CbGpPWpGaD
Erlotinib—EGFR—Immune System—FGFR1—cleft lip	9.57e-05	0.000123	CbGpPWpGaD
Erlotinib—CYP3A5—Metabolism—MTR—cleft lip	9.55e-05	0.000122	CbGpPWpGaD
Erlotinib—EGFR—Disease—FGFR2—cleft lip	9.48e-05	0.000121	CbGpPWpGaD
Erlotinib—EGFR—Disease—MTHFR—cleft lip	9.13e-05	0.000117	CbGpPWpGaD
Erlotinib—EGFR—Immune System—FGFR3—cleft lip	9.05e-05	0.000116	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism—MTR—cleft lip	9.02e-05	0.000116	CbGpPWpGaD
Erlotinib—CYP1B1—Metabolism—TYMS—cleft lip	8.98e-05	0.000115	CbGpPWpGaD
Erlotinib—MKNK1—Signaling Pathways—MYC—cleft lip	8.96e-05	0.000115	CbGpPWpGaD
Erlotinib—EGFR—Disease—FGFR1—cleft lip	8.84e-05	0.000113	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—FGF2—cleft lip	8.42e-05	0.000108	CbGpPWpGaD
Erlotinib—UGT1A1—Metabolism—MTHFR—cleft lip	8.41e-05	0.000108	CbGpPWpGaD
Erlotinib—EGFR—Disease—FGFR3—cleft lip	8.35e-05	0.000107	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—NOS3—cleft lip	8.31e-05	0.000106	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—TCN2—cleft lip	8.3e-05	0.000106	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—FGF10—cleft lip	8.27e-05	0.000106	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism—MTR—cleft lip	8.27e-05	0.000106	CbGpPWpGaD
Erlotinib—ALB—Metabolism—MTR—cleft lip	8.22e-05	0.000105	CbGpPWpGaD
Erlotinib—ABL1—Immune System—FGF2—cleft lip	8.18e-05	0.000105	CbGpPWpGaD
Erlotinib—ABCG2—Metabolism—TYMS—cleft lip	8.17e-05	0.000105	CbGpPWpGaD
Erlotinib—CYP1B1—Metabolism—MTHFR—cleft lip	7.84e-05	0.0001	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—SLC19A1—cleft lip	7.73e-05	9.9e-05	CbGpPWpGaD
Erlotinib—ALB—Hemostasis—NOS3—cleft lip	7.58e-05	9.7e-05	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—MTR—cleft lip	7.21e-05	9.23e-05	CbGpPWpGaD
Erlotinib—ABCG2—Metabolism—MTHFR—cleft lip	7.14e-05	9.14e-05	CbGpPWpGaD
Erlotinib—EGFR—Immune System—FGF2—cleft lip	6.99e-05	8.96e-05	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—MTR—cleft lip	6.79e-05	8.7e-05	CbGpPWpGaD
Erlotinib—JAK3—Signaling Pathways—MYC—cleft lip	6.76e-05	8.65e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—FGFR2—cleft lip	6.64e-05	8.51e-05	CbGpPWpGaD
Erlotinib—EGFR—Disease—FGF2—cleft lip	6.46e-05	8.27e-05	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—TCN2—cleft lip	6.41e-05	8.21e-05	CbGpPWpGaD
Erlotinib—EGFR—Disease—NOS3—cleft lip	6.37e-05	8.16e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—FGFR1—cleft lip	6.19e-05	7.93e-05	CbGpPWpGaD
Erlotinib—UGT1A1—Metabolism—NOS3—cleft lip	5.87e-05	7.51e-05	CbGpPWpGaD
Erlotinib—CYP3A5—Metabolism—TYMS—cleft lip	5.85e-05	7.5e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—FGFR3—cleft lip	5.85e-05	7.49e-05	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—MTR—cleft lip	5.75e-05	7.37e-05	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism—TYMS—cleft lip	5.53e-05	7.08e-05	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—MYC—cleft lip	5.51e-05	7.05e-05	CbGpPWpGaD
Erlotinib—CYP1B1—Metabolism—NOS3—cleft lip	5.47e-05	7.01e-05	CbGpPWpGaD
Erlotinib—CYP3A5—Metabolism—MTHFR—cleft lip	5.11e-05	6.55e-05	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism—TYMS—cleft lip	5.07e-05	6.49e-05	CbGpPWpGaD
Erlotinib—ALB—Metabolism—TYMS—cleft lip	5.04e-05	6.46e-05	CbGpPWpGaD
Erlotinib—ABCG2—Metabolism—NOS3—cleft lip	4.98e-05	6.38e-05	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism—MTHFR—cleft lip	4.83e-05	6.19e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—FGF2—cleft lip	4.52e-05	5.79e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—NOS3—cleft lip	4.46e-05	5.71e-05	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—MTR—cleft lip	4.44e-05	5.69e-05	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism—MTHFR—cleft lip	4.43e-05	5.67e-05	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—TYMS—cleft lip	4.42e-05	5.66e-05	CbGpPWpGaD
Erlotinib—ALB—Metabolism—MTHFR—cleft lip	4.4e-05	5.64e-05	CbGpPWpGaD
Erlotinib—EGFR—Disease—MYC—cleft lip	4.22e-05	5.41e-05	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—TYMS—cleft lip	4.16e-05	5.33e-05	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—MTHFR—cleft lip	3.86e-05	4.94e-05	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—MTHFR—cleft lip	3.64e-05	4.66e-05	CbGpPWpGaD
Erlotinib—CYP3A5—Metabolism—NOS3—cleft lip	3.57e-05	4.57e-05	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—TYMS—cleft lip	3.53e-05	4.52e-05	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism—NOS3—cleft lip	3.37e-05	4.32e-05	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism—NOS3—cleft lip	3.09e-05	3.96e-05	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—MTHFR—cleft lip	3.08e-05	3.95e-05	CbGpPWpGaD
Erlotinib—ALB—Metabolism—NOS3—cleft lip	3.07e-05	3.93e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—MYC—cleft lip	2.96e-05	3.79e-05	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—TYMS—cleft lip	2.72e-05	3.49e-05	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—NOS3—cleft lip	2.69e-05	3.45e-05	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—NOS3—cleft lip	2.54e-05	3.25e-05	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—MTHFR—cleft lip	2.38e-05	3.05e-05	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—NOS3—cleft lip	2.15e-05	2.75e-05	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—NOS3—cleft lip	1.66e-05	2.12e-05	CbGpPWpGaD
